New Subtype of Prostate Cancer

Author | Nicole Fawcett

Image by Alexander Tokarev for Ella Maru Studio

Researchers at U-M's Rogel Cancer Center have identified a new subtype of prostate cancer that occurs in about 7 percent of patients with advanced disease. The subtype is characterized by loss of the gene CDK12. It was found to be more common in metastatic prostate cancer compared with early-stage tumors that had not spread. 

Tumors in which CDK12 was inactivated were responsive to immune checkpoint inhibitors, a type of immunotherapy treatment that overall has had limited success in prostate cancer. "Because prostate cancer is so common, 7 percent is a significant number. The fact that immune checkpoint inhibitors may be effective against this subtype of prostate cancer makes it even more significant. This is an exciting prospect for patients who have CDK12 alterations and may benefit from immunotherapy," says senior study author Arul Chinnaiyan (M.D. and Ph.D. 1999), director of the Michigan Center for Translational Pathology and the S.P. Hicks Professor of Pathology. 

In the study, published in Cell, researchers looked at DNA and RNA sequencing data from 360 tumor samples from patients with metastatic castration-resistant prostate cancer. This is an aggressive, advanced form of the disease in which the cancer has spread throughout the body and no longer responds to traditional hormone-based treatments. Tumor samples were from U-M's Mi-ONCOSEQ program and from samples collected through the Stand Up to Cancer-Prostate Cancer Foundation Dream Team. 

Researchers at the Rogel Cancer Center will lead a multisite clinical trial to assess checkpoint inhibitors as a treatment for metastatic prostate cancer with CDK12 loss. 

More Articles About: Prostate Cancer Research Rogel Cancer Center immunotherapy
Featured News & Stories
News Release
Eight U-M researchers win PECASE awards
Three U-M medical researchers, and five others from the U-M faculty, have received one of the nation's top honors for scientists and engineers, as announced by the White House.
 Minding Memory with a microphone and a shadow of a microphone on a blue background
Minding Memory
Understanding Dementia Risk Factors with Helen C. Kales, MD
In this episode, Matt & Lauren have the unique opportunity to talk with Dr. Helen C. Kales, a geriatric psychiatrist and health services researcher who has participated in the previous Lancet Commissions on Dementia Prevention, Intervention and Care – including the most recent one released in 2024. Dr. Kales discusses how the commission puts together all the evidence to make recommendations that can play a crucial role in dementia prevention. Dr. Kales is the Chair of the Department of Psychiatry and Behavioral Sciences and Joe P. Tupin Professor of Psychiatry at the University of California at Davis and has dedicated much of her career to improving the lives of patients living with dementia.
 PURPLE BLUE RED CELLS FLOATING
Health Lab
Using cellular therapy to treat cancer, and beyond
Here, Monalisa Ghosh, M.D., a hematologist-oncologist at the University of Michigan Health Rogel Cancer Center, answers questions about cellular therapy; how it's used and what exciting developments are soon to come.
 patient looking at paper with provider in scrubs blue in clinic
Health Lab
How race impacts patients’ response to cancer immunotherapy
The first large scale analysis finds immune checkpoint inhibitors are equally effective in Black and white patients, with Black patients having fewer side effects.
 Minding Memory with a microphone and a shadow of a microphone on a blue background
Minding Memory
Greenspace and Late-Life Cognitive Decline
In this episode Matt and Lauren will speak with Dr. Marcia Pescador Jimenez, an Assistant Professor in the Department of Epidemiology at Boston University whose research focuses on understanding the relationship between exposure to green space and health outcomes (including hypertension and cognitive measures). Emerging research has shown that midlife risk factors may delay or even prevent the onset of dementia later in life - among these include physical activity and social interaction. It’s not a stretch to imagine how a person’s environment may impact behaviors such as physical activity. For instance, there are places that lack sidewalks and parks that make exercising exceedingly difficult. Among environmental epidemiologists, there is growing interest in understanding how the built and natural environment influence our behaviors that, in turn, influence our health. We encourage you to listen to this episode while on a walk outside!
 Sahiti Marella in the lab
Office of Research
2024 Research Annual Report Released
Medical School releases 2024 Research Annual Report